Optivus Proton Therapy, Inc. Teams with Parsons Commercial Technology Group
Inc. to Produce Proton Beam Treatment Centers Globally
LOS ANGELES, Oct. 29 /PRNewswire/ -- Yesterday, at the 49th Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO), Optivus Proton Therapy, Inc. (Optivus(R)) and Parsons Commercial Technology Group Inc., a global business unit of Parsons Corporation, announced a historic teaming agreement has been formalized between the two companies to globally produce turn-key proton beam therapy centers.
"The agreement between the teams of Optivus and Parsons will assure our clients that their proton system will be completed on time by the most expert team in the field," said Jon Slater, Optivus President and CEO. "This is a win/win/win situation for Optivus, Parsons and our clients."
Founded in 1944, Parsons is one of the largest 100% employee-owned management, engineering, and construction companies in the United States.
"Parsons collaborates with innovators and leaders in many diversified markets. We are thrilled to add the development of proton beam therapy centers, with Optivus, to our wide-ranging portfolio," said John Small, Parsons Group President.
Optivus was formed by the engineers who designed and installed the world's first and most successful hospital-based proton center at Loma Linda University Medical Center in Loma Linda, California. The facility commissioned and maintained by Optivus has enjoyed more success than all other comparable competitors' systems, with higher throughput, the most patients treated, and the most types of diseases treated with the most reliable and efficient device on the market.
"Interest in the development of proton treatment centers has grown at an enormous rate in recent years and can largely be attributed to our successes," Slater said. "This development will further reinforce our position as the global leader in proton therapy technology," he added.
The Southern California-based Optivus Parsons team will meet the market demand for the development of proton therapy using Optivus' patented and proven technology.
"The global success and leadership of Parsons guarantees our ability to develop multiple proton centers simultaneously with a consistent level of resources and integrity," said Slater.
"The Optivus Parsons teaming agreement is a milestone for both companies," said Small. "We share Optivus' dedication and commitment to patients who will benefit from the life-saving proton treatment technology for which they've set the gold standard."
Representatives from Parsons will be in attendance at the Optivus booth 501 during ASTRO for Q & A.
ABOUT OPTIVUS AND PARSONS
Optivus Proton Therapy, Inc. is a pioneer in the field of proton therapy technology. Optivus' patented, FDA-cleared modular Proton Beam Therapy System (PBTS), the Conforma 3000(R), leads the industry in patient throughput, highest operational reliability and safety. To date, the Optivus system has delivered nearly half a million individual patient treatments with a perfect safety record. For more information about Optivus, visit http://www.optivus.com.
Parsons, celebrating more than 60 years of setting industry standards, is a leader in many diversified markets such as healthcare, education and public buildings, infrastructure, water, transportation, construction, planning, commercial, industrial manufacturing, communications, environmental, life sciences, critical facilities, nuclear and special materials, and homeland security. Parsons provides technical and management solutions to private industrial customers worldwide, as well as federal, regional, and local government agencies. For more information about Parsons, visit http://www.parsons.com.
Optivus Proton Therapy, Inc.
Parsons Group President
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
|SOURCE Optivus Proton Therapy, Inc.|
Copyright©2007 PR Newswire.
All rights reserved